Is Play Health profitable?

No. As of July 2026 Play Health has no reported revenue, only a $500K convertible note raised around October 2025, and a team of about 4 employees, making profitability far off for this seed-stage startup.

Could AI replace Play Health?

Its core feature, AI-generated symptom insights after 28 days of tracking, is directly replicable by larger players; Midi Health already ships an AI-powered women's health search tool at scale as of February 2026, exposing Play Health's insight layer to commoditization.

Who is Play Health's biggest competitor?

Midi Health, which crossed a $1B+ valuation after a $100M Series D in February 2026 and is described as the fastest growing women's telehealth company, insurance-accepting at scale, dwarfing Play Health's ~4-person, $500K-funded team.

Who owns Play Health?

Play Health is a privately held, founder-led startup backed by Y Combinator and Rebel Fund, part of YC's Fall 2025 batch; no parent company or priced equity round has been publicly disclosed as of 2026.

Has Play Health raised much funding?

Only a $500K convertible note reported around October 1, 2025, according to CBInsights; no priced seed or Series A round has been publicly disclosed as of mid-2026, versus rival Midi Health's $1B+ valuation.

Does Play Health have paying enterprise customers?

As of a July 10, 2026 market mapping report, no named health-system or enterprise logos or confirmed customer deployments for Play Health's clinician-facing Nav product have been publicly found.

YC Fall 2025 · United States

Play Health

Early-stage perimenopause app pivoting to clinical decision support infrastructure for providers.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from Q2 2026 · Every call on the record Checkpoint: Target window for Play Health to land 2-3 signed health-system design partners

The call

A six-month-old pivot with no signed health-system customers sits in the same window a $1B rival could close with one announcement.

Play Health makes software that helps doctors and clinics manage hormone treatments by using AI to read test results and symptoms. Right now it is hard to tell if Play Health can survive because Midi Health, a bigger company in the same space, already has paying customers, more money, and its own AI tools working at scale. Midi Health could fairly easily build the same kind of doctor-focused software Play Health is trying to make, especially since Play Health has no announced customers yet and has only been trying this new direction for six months. The one thing that matters most: whether Play Health can get real doctors and hospitals to actually use and pay for its software in the next year, or whether Midi Health announces it is going after the same customers first.

Why

AI pressure: Midi Health's AI-powered search and insight tool. Midi already ships AI insight generation on symptom and hormone data, the same layer Play Health's product depends on. Could AI do the core job? Yes, likely.

Bigger players: Midi Health. Midi Health just crossed $1B valuation and could build its own B2B infrastructure arm, but has not announced one yet. Could a giant copy it? Yes, easily.

What protects it. Positioning as neutral infrastructure for existing providers rather than a competing clinic, plus an unbuilt longitudinal symptom-plus-hormone dataset if it ever gets built.

What would change this call

Midi Health launches a B2B or health-system CDS/infrastructure product within 18 to 24 months. Would close Play Health's structural window and prove Midi can out-build it.
Play Health announces 2 to 3 named, signed health-system design partners by Q2 2026. Would show the pivot to infrastructure is gaining real traction, not just messaging.
Maven Clinic releases a menopause CDS module for employer or health-system buyers. Would show a second well-funded rival entering the same infrastructure niche.

Key numbers

Midi Health: $100M Series D, over $1B valuation (2026-02-03)
Play Health headcount: about 4 employees (2026-05-29)
Addressable pool cited: 30M+ US women with symptoms (2025-10-14)

Named risks

Only $500K convertible note and ~4 staff with no priced round disclosed as of mid-2026. Severity: high
Zero named health-system or enterprise customers confirmed as of July 2026. Severity: high
Six-month-old pivot from consumer app to infrastructure positioning remains untested. Severity: medium
Core AI insight-generation layer replicable by incumbents like Midi Health's AI search tool. Severity: medium
Category consolidating around well-capitalized rivals, squeezing smaller data-layer entrants. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Midi Health	losing to	Midi hit >$1B valuation via $100M Series D Feb 2026 vs Play Health's $500K note
Maven Clinic	contesting	Maven (~$1.3B+ valuation) expanding into menopause care as of Mar 2026, threatens B2B pipeline
Alloy Health	contesting	Leaner ~$21M-funded menopause telehealth rival competing on retention as of Jul 2026
Elektra Health	contesting	Smaller NY digital menopause platform, ~17 employees, founded 2019

Questions people ask

Is Play Health profitable?: No. As of July 2026 Play Health has no reported revenue, only a $500K convertible note raised around October 2025, and a team of about 4 employees, making profitability far off for this seed-stage startup.
Could AI replace Play Health?: Its core feature, AI-generated symptom insights after 28 days of tracking, is directly replicable by larger players; Midi Health already ships an AI-powered women's health search tool at scale as of February 2026, exposing Play Health's insight layer to commoditization.
Who is Play Health's biggest competitor?: Midi Health, which crossed a $1B+ valuation after a $100M Series D in February 2026 and is described as the fastest growing women's telehealth company, insurance-accepting at scale, dwarfing Play Health's ~4-person, $500K-funded team.
Who owns Play Health?: Play Health is a privately held, founder-led startup backed by Y Combinator and Rebel Fund, part of YC's Fall 2025 batch; no parent company or priced equity round has been publicly disclosed as of 2026.
Has Play Health raised much funding?: Only a $500K convertible note reported around October 1, 2025, according to CBInsights; no priced seed or Series A round has been publicly disclosed as of mid-2026, versus rival Midi Health's $1B+ valuation.
Does Play Health have paying enterprise customers?: As of a July 10, 2026 market mapping report, no named health-system or enterprise logos or confirmed customer deployments for Play Health's clinician-facing Nav product have been publicly found.

Timeline

2026-07-10Market report finds Play Health has zero named health-system customers or deployments
2026-04-15Play Health repositions messaging from consumer app to perimenopause infrastructure play
2026-03-24Play Health app becomes available on Android with wearable integrations
2026-02-03Rival Midi Health raises $100M Series D, crossing $1B valuation
2025-10-26Play Health consumer app launches on iOS, tracking 40+ symptoms
2025-10-21Press coverage of Play Health's YC-backed launch published
2025-10-14Play Health publicly launches via Y Combinator Launch YC
2025-10-01Play Health raises $500K convertible note
2025Play Health founded and joins Y Combinator Fall 2025 batch

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Nexus Terrain Metorial